Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy

Anticancer Research

Volumn 35, Issue 10, 2015, Pages 5679-5686

  Thalgott, Mark ^a   Rack, Brigitte ^b   Horn, Thomas ^a   Heck, Matthias M ^a   Eiber, Matthias ^a   Kübler, Hubert ^a   Retz, Margitta ^a   Gschwend, Jürgen E ^a   Andergassen, Ulrich ^b   Nawroth, Roman ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomarkers; Circulating tumor cells; CTCs; Molecular marker; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL TIME; ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; DISEASE COURSE; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR; SURVIVAL RATE; TUMOR EMBOLISM; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 84942813773     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH and Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13): 981-90, 2002.
2. Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Baez LL, Sesterhenn IA, McLeod DG, Moul JW and Srivastava S: Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res 9(7): 2545-50, 2003.
3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F and Mottet N; European Association of Urology: EAU guidelines on prostate cancer. Part I: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1): 124-37, 2014.
4. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM and Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771, 1998.
5. Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, Autenrieth M, Herkommer K, Krause BJ, Gschwend JE, Treiber U and Kübler HR: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol 5(7): 20, 2014.
6. Brawer MK, Benson MC, Bostwick DG, Djavan B, Lilja H, Semjonow A, Su S and Zhou Z: Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 17(4): 206-21, 1999.
7. Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T and Babaian RJ: Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179(6): 2187-91, 2008.
8. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ and Ward DC: Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9(1): 39-45, 2011.
9. Bono de JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19): 6302-6309, 2008.
10. Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG and Terstappen LW: Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 58(3): 386-92, 2001.
11. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 15;10(20): 6897-904, 2004.
12. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA and Maheswaran S: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2(25): 25ra23, 2010.
13. Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C and Koutsilieris M: Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15(3-4): 101-114, 2009.
14. Okegawa T, Itaya N, Hara H, Tambo M and Nutahara K: Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res 34(11): 6705-6710, 2014.
15. Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kre V, Heck MM, Andergassen U, Nawroth R, Gschwend JE and Retz M: Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol 139(5): 755-763, 2013.
16. Hartkopf AD, Wagner P, Wallwiener D, Fehm T and Rothmund R: Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 31(3): 979-984, 2011.
17. Sobin LH, Wittekind CH. Urological tumours. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. Geneva: UICC; 2002. p. 179-206.
18. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F and Mottet N: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2): 467-479, 2014.
19. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Robin Vollmer and Wilding G: Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17(11): 3461-3467, 1999.
20. Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J and Olivier Gómez C: Prognostic significance of circulating tumor cell count in patients with metastatic hormonesensitive prostate cancer. Urology 80(6): 1328-1332, 2012.
21. Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, Nelson C and Martin J: Circulating tumor cell detection in highrisk non-metastatic prostate cancer. J Cancer Res Clin Oncol 140(12): 2157-2162, 2014.
22. Steuber T, Schlomm T, Heinzer H, Becker A, Pantel K and Riethdorf S: Prävalenz und prognostischer Wert von zirkulierenden Tumorzellen (CTC) im Blut von Patienten mit einem lokalisierten Prostatakarzinom vor radikaler Prostatektomie: Der Urologe 51, Issue: Supplement, 2012.
23. Pantel K and Alix-Panabières C: Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 73(21): 6384-6388, 2013.
24. Grasso YZ, Gupta MK, Levin HS, Zippe CD and Klein EA: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1;58(7): 1456-1459, 1998.
25. Rink M, Chun FK, Minner S, Friedrich M, Mauermann O, Heinzer H, Huland H, Fisch M, Pantel K and Riethdorf S: Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 107(10): 1668-1675, 2011.
26. Skondra M, Gkioka E, Kostakis ID, Pissimissis N, Lembessis P, Pectasides D and Koutsilieris M: Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features. Anticancer Res 34(11): 6691-6699, 2014.
27. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G and Pantel K: Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9): 2634-2645, 2010.
28. Eschwège P, Moutereau S, Droupy S, Douard R, Gala JL, Benoit G, Conti M, Manivet P and Loric S: Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer 24;100(4): 608-610, 2009.
29. Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M and Bobek V: Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to Tstage and Gleason score. Anticancer Res 34(7): 3641-3646, 2014.
30. Thalgott M, Heck MM and Pantel K: Detection of circulating tumor cells from peripheral blood in prostate cancer. Urologe A 53(4): 509-513, 2014.